Evidence map›Paper›PMID 36185843›Full record

ReviewCureus2022

Role of Serotoninergic Antidepressants in the Development of Autism Spectrum Disorders: A Systematic Review.

Sheena Mathew, Sumahitha Bichenapally, Vahe Khachatryan, Asmaa Muazzam, Chandani Hamal, Lakshmi Sai Deepak Reddy Velugoti, Godfrey Tabowei, Greeshma N Gaddipati, Maria Mukhtar, Mohammed J Alzubaidee and 2 more

Abstract readReview
In one paragraph

Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sheena MathewPediatrics, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Sumahitha BichenapallyInternal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Vahe KhachatryanInternal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Asmaa MuazzamPathology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Chandani HamalInternal Medicine/Family Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Lakshmi Sai Deepak Reddy VelugotiResearch, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Godfrey TaboweiResearch, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Greeshma N GaddipatiResearch, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Maria MukhtarResearch, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Mohammed J AlzubaideeInternal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Raga Sruthi DwarampudiResearch, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Michael AlfonsoMedicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autism spectrum disorders (ASDs) are one of the most common, highly heritable neurodevelopmental diseases affecting 1-2% of children under the age of 3. Although studies have implicated genetic predispositions, environmental risk factors, and maternal depression as the pathophysiology of ASD, it remains unclear. The association between antidepressant (AD) usage during pregnancy and the likelihood of ASD in children is still debatable. We carried out a systematic review to determine the relation of ASD with AD in offspring exposed to ADs in utero. We used the following terms of medical subject heading (MeSH) and keywords separately and in combination: "antidepressants," "maternal/pregnancy depression," "autism spectrum disorders/autism," and "selective serotonin reuptake inhibitors (SSRI)." Our data search was conducted on PubMed, PubMed Central, Google Scholar, and Cochrane, which resulted in 28,141 articles. We identified and eliminated duplicates and then screened 9,965 articles by title and abstract. We then applied eligibility criteria over 143 relevant articles; a quality assessment was performed, and finally we included 18 selected studies. Mothers who had taken ADs during pregnancy for at least two medication prescription cycles and children detected to have ASD from two years to 18 years of age were included. We excluded articles in languages other than English, grey literature, case reports, letters to the editor, books, documents, animal studies, and studies published before 2017. Out of 18 studies, 17 evaluated ASD as the primary outcome, and for one study, the outcome was child behavioral as well as neurodevelopmental changes. Other additional outcomes studied were attention deficit hyperactivity disorder (ADHD), preterm birth, spontaneous abortion, small for gestational age, maternal mental illness, and persistent pulmonary hypertension. After adjusting for confounding factors, in six studies, the higher correlations between ASD and ADs were eliminated. Also, paternal AD use, maternal pre-conceptional AD drug use, and maternal depression itself are additional factors that raise the incidence of ASD.

Indexed as

antidepressantsautism specrum disordersgestational agematernal depressionpregnancyselective serotonin reuptake inhibitors

Identifiers

PMID36185843
PMCPMC9514805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.